This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (62)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Tremor  • Alert me on articles by topic

Joseph Jankovic, MD; Asha S. Kapadia, PhD

Arch Neurol. 2001;58:1611-1615.

Objectives  To determine the overall rate of functional decline and to assess the progression of different signs of Parkinson disease (PD).

Patients and Methods  Patients with clinically diagnosed PD followed up for at least 3 years were included in this study. Demographic and clinical data (including the Unified Parkinson's Disease Rating Scale [UPDRS]) were analyzed by the multivariate unbalanced repeated-measurements design using the mixed-effects model to study the association between different symptoms and various demographic variables. Regression models helped estimate the rates of progression of the disease in relationship to the various components of the UPDRS. Patients were categorized as having tremor-dominant or postural instability–gait difficulty–dominant PD and the 2 categories were compared for progression of their total UPDRS scores.

Design  A multivariate mixed-effects model was used to study the relationship between the different symptoms and various demographic variables. Nonparametric statistical tests were used to compare the progression of symptoms in the "on" (good function) state and the "off" (poor function) state groups for 2 age-at-onset categories (57 and >57 years).

Results  Data from 1731 visits on 297 patients (181 men) followed up for an average of 6.36 years (range, 3-17 years) were analyzed. The annual rate of decline in the total UPDRS scores was 1.34 when assessed during the on state and 1.58 when assessed during the off state. Patients with an older age at onset had more rapid progression of PD than those with a younger age at onset. Furthermore, the older-onset group had statistically significantly more progression in mentation, freezing, and parts I (mentation) and II (activities of daily living) UPDRS subscores. Handwriting was the only component of the UPDRS score that did not notably deteriorate during the observation period. Regression analysis of 108 patients whose symptoms were rated during their off state showed a faster rate of cognitive decline as age at onset increased. The slopes (ie, the annual rates of decline) of progression in the UPDRS scores, when adjusted for age at the initial visit, were steeper for the postural instability–gait difficulty–dominant group compared with the tremor-dominant group.

Conclusion  Based on longitudinal follow-up data, our findings provide evidence for a variable course of progression of the different PD symptoms, thus implying different biochemical or degenerative mechanisms for the various clinical features associated with PD.

From the Department of Neurology, Baylor College of Medicine (Dr Jankovic), and the School of Public Health, University of Texas (Dr Kapadia), Houston.

Corresponding author: Joseph Jankovic, MD, Department of Neurology, 6550 Fannin, No. 1801, Houston, TX 77030 (e-mail: josephj{at}bcm.tmc.edu).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serum Uric Acid and Clinical Progression in Parkinson Disease: Potential Biomarker for Nigrostriatal Failure
Schiess and Oh
Arch Neurol 2008;65:698-699.
FULL TEXT  

Parkinson's disease: clinical features and diagnosis
Jankovic
J. Neurol. Neurosurg. Psychiatry 2008;79:368-376.
ABSTRACT | FULL TEXT  

A Whole-Brain Analysis in De Novo Parkinson Disease
Tessa et al.
Am. J. Neuroradiol. 2008;29:674-680.
ABSTRACT | FULL TEXT  

Endurance Exercise Training to Improve Economy of Movement of People With Parkinson Disease: Three Case Reports
Schenkman et al.
ptjournal 2008;88:63-76.
ABSTRACT | FULL TEXT  

The Relationship of Parkinson Disease With Aging
Levy
Arch Neurol 2007;64:1242-1246.
ABSTRACT | FULL TEXT  

Characteristics of orthostatic hypotension in Parkinson's disease
Oka et al.
Brain 2007;0:awm174v1-8.
ABSTRACT | FULL TEXT  

Gender differences in Parkinson's disease
Haaxma et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:819-824.
ABSTRACT | FULL TEXT  

Patterns of levodopa response in Parkinson's disease: a clinico-pathological study
Kempster et al.
Brain 2007;130:2123-2128.
ABSTRACT | FULL TEXT  

Changes in network activity with the progression of Parkinson's disease
Huang et al.
Brain 2007;130:1834-1846.
ABSTRACT | FULL TEXT  

Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
Wider et al.
Arch Neurol 2006;63:951-955.
ABSTRACT | FULL TEXT  

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies
Burn et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:585-589.
ABSTRACT | FULL TEXT  

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Suchowersky et al.
Neurology 2006;66:968-975.
ABSTRACT | FULL TEXT  

Parkinson disease with severe tremor but otherwise mild deterioration.
O'Suilleabhain
Arch Neurol 2006;63:321-322.
FULL TEXT  

Progression of motor impairment and disability in Parkinson disease: A population-based study
Alves et al.
Neurology 2005;65:1436-1441.
ABSTRACT | FULL TEXT  

Progression of Parkinson Disease: Are We Making Progress in Charting the Course?
Jankovic
Arch Neurol 2005;62:351-352.
FULL TEXT  

Nonlinear Progression of Parkinson Disease as Determined by Serial Positron Emission Tomographic Imaging of Striatal Fluorodopa F 18 Activity
Hilker et al.
Arch Neurol 2005;62:378-382.
ABSTRACT | FULL TEXT  

Contribution of Aging to the Severity of Different Motor Signs in Parkinson Disease
Levy et al.
Arch Neurol 2005;62:467-472.
ABSTRACT | FULL TEXT  

Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa
Marek et al.
Neurology 2003;61:S43-48.
FULL TEXT  

Parkinson's disease and anaesthesia
Nicholson et al.
Br J Anaesth 2002;89:904-916.
ABSTRACT | FULL TEXT  

Predicting Motor Decline and Disability in Parkinson Disease: A Systematic Review
Marras et al.
Arch Neurol 2002;59:1724-1728.
ABSTRACT | FULL TEXT  

Levodopa strengths and weaknesses
Jankovic
Neurology 2002;58:S19-32.
ABSTRACT | FULL TEXT  

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Suchowersky et al.
Neurology 2006;66:968-975.
ABSTRACT | FULL TEXT